Sumitomo Mitsui Trust Group Inc. Invests $728,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sumitomo Mitsui Trust Group Inc. acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 6,637 shares of the medical equipment provider's stock, valued at approximately $728,000.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 208 shares during the period. Signaturefd LLC lifted its position in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 92 shares in the last quarter. Nkcfo LLC purchased a new stake in shares of Lantheus in the second quarter valued at $47,000. UMB Bank n.a. lifted its position in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after buying an additional 126 shares during the period. Finally, Kathleen S. Wright Associates Inc. purchased a new position in Lantheus during the third quarter worth about $51,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. B. Riley increased their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. Redburn Atlantic assumed coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective for the company. StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Friday, November 8th. JMP Securities reduced their price target on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 7th. Finally, Truist Financial reiterated a "buy" rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $122.50.

Lantheus Price Performance

Lantheus stock traded up $7.02 during mid-day trading on Wednesday, hitting $86.45. 2,026,315 shares of the company's stock traded hands, compared to its average volume of 1,014,213. The firm has a 50 day simple moving average of $103.76 and a two-hundred day simple moving average of $96.59. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The stock has a market cap of $6.01 billion, a price-to-earnings ratio of 14.38 and a beta of 0.51.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.